Mujeres posmenopáusicas | 23 JUL 12

¿Cuál es el lapso entre cada densitometría para detectar la osteoporosis?

Las tasas de densitometrías para el cribado de la osteoporosis en mujeres posmenopáusicas son inferiores a las recomendadas por las guías actuales.
Autor/a: Dres. Elaine W. Yu, Joel S. Finkelstein. JAMA, June 27, 2012—Vol 307, No. 24
INDICE:  1. Artículo | 2. Artículo
Artículo

1. King AB, Fiorentino DM. Medicare payment cuts for osteoporosis testing reduced use despite tests’ benefit in reducing fractures. Health Aff (Millwood). 2011; 30(12):2362-2370.

2. US Preventive Services Task Force. Screening for osteoporosis: recommendation statement. Am Fam Physician. 2011;83(10):1197-1200.

3. National Osteoporosis Foundation. NOF Clinician’s Guide to Prevention and Treatment of Osteoporosis. http://www.nof.org/professionals/clinical-guidelines. Accessed February 11, 2012.

4. Nguyen TV, Center JR, Eisman JA. Femoral neck bone loss predicts fracture risk independent of baseline BMD. J Bone Miner Res. 2005;20(7):1195-1201.

5. Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(2):155-160.

6. Gourlay ML, Fine JP, Preisser JS, et al; Study of Osteoporotic Fractures Research Group. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225-233.

7. Wainwright SA, Marshall LM, Ensrud KE, et al; Study of Osteoporotic Fractures Research Group. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90(5):2787-2793.

8. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX/tool.jsp. Accessed April 16, 2012.

9. Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM; Fracture Intervention Trial Research Group. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to −2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005;80(3):343-349.

10. Siris ES, Simon JA, Barton IP, McClung MR, Grauer A. Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int. 2008; 19(5):681-686. VIEWPOINT 2592 JAMA, June 27, 2012—Vol 307, No. 24 ©2012 American Medical Association. All rights reserved.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024